Loading...

Cesca Therapeutics

Nasdaq:KOOL
Snowflake Description

High growth potential with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
KOOL
Nasdaq
$7M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies for cell-based therapies in the United States, China, rest of Asia, Europe, and internationally. The last earnings update was 41 days ago. More info.


Add to Portfolio Compare Print
KOOL Share Price and Events
7 Day Returns
-0.4%
NasdaqCM:KOOL
3%
US Medical Equipment
2%
US Market
1 Year Returns
-38.9%
NasdaqCM:KOOL
16.5%
US Medical Equipment
4.3%
US Market
KOOL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cesca Therapeutics (KOOL) -0.4% 8.6% -0.6% -38.9% -90.1% -99%
US Medical Equipment 3% 8.1% 5.6% 16.5% 68.9% 101.1%
US Market 2% 4.1% 4.2% 4.3% 43.9% 40.8%
1 Year Return vs Industry and Market
  • KOOL underperformed the Medical Equipment industry which returned 16.5% over the past year.
  • KOOL underperformed the Market in United States of America which returned 4.3% over the past year.
Price Volatility
KOOL
Industry
5yr Volatility vs Market

KOOL Value

 Is Cesca Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Cesca Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $2.7801.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cesca Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cesca Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:KOOL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-17.69
NasdaqCM:KOOL Share Price ** NasdaqCM (2019-06-24) in USD $2.78
United States of America Medical Equipment Industry PE Ratio Median Figure of 64 Publicly-Listed Medical Equipment Companies 41.58x
United States of America Market PE Ratio Median Figure of 3,095 Publicly-Listed Companies 17.88x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cesca Therapeutics.

NasdaqCM:KOOL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:KOOL Share Price ÷ EPS (both in USD)

= 2.78 ÷ -17.69

-0.16x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cesca Therapeutics is loss making, we can't compare its value to the US Medical Equipment industry average.
  • Cesca Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Cesca Therapeutics's expected growth come at a high price?
Raw Data
NasdaqCM:KOOL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.16x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
68%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 56 Publicly-Listed Medical Equipment Companies 2.32x
United States of America Market PEG Ratio Median Figure of 2,134 Publicly-Listed Companies 1.54x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cesca Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cesca Therapeutics's assets?
Raw Data
NasdaqCM:KOOL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $2.40
NasdaqCM:KOOL Share Price * NasdaqCM (2019-06-24) in USD $2.78
United States of America Medical Equipment Industry PB Ratio Median Figure of 183 Publicly-Listed Medical Equipment Companies 4.6x
United States of America Market PB Ratio Median Figure of 5,255 Publicly-Listed Companies 1.8x
NasdaqCM:KOOL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:KOOL Share Price ÷ Book Value per Share (both in USD)

= 2.78 ÷ 2.40

1.16x

* Primary Listing of Cesca Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cesca Therapeutics is good value based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess Cesca Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Cesca Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

KOOL Future Performance

 How is Cesca Therapeutics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
68%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cesca Therapeutics expected to grow at an attractive rate?
  • Cesca Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Cesca Therapeutics's earnings growth is expected to exceed the United States of America market average.
  • Cesca Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:KOOL Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:KOOL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 68%
NasdaqCM:KOOL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 21.8%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.9%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:KOOL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:KOOL Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 33 1 1
2022-12-31 28 -1 1
2021-12-31 24 -3 1
2020-12-31 18 -5 1
2019-12-31 14 -6 1
NasdaqCM:KOOL Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 11 -7 -39
2018-12-31 10 -7 -40
2018-09-30 10 -9 -32
2018-06-30 10 -9 -32
2018-03-31 11 -7 -6
2017-12-31 13 -8 -6
2017-09-30 14 -7 -9
2017-06-30 15 -7 -29
2017-03-31 14 -6 -32
2016-12-31 14 -8 -40
2016-09-30 13 -10 -38
2016-06-30 12 -10 -19

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Cesca Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Cesca Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:KOOL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Cesca Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:KOOL Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.20 0.20 0.20 1.00
2022-12-31 -0.20 -0.20 -0.20 1.00
2021-12-31 -0.60 -0.60 -0.60 1.00
2020-12-31 -1.00 -1.00 -1.00 1.00
2019-12-31 -2.00 -2.00 -2.00 1.00
NasdaqCM:KOOL Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -17.69
2018-12-31 -21.57
2018-09-30 -21.88
2018-06-30 -27.40
2018-03-31 -6.24
2017-12-31 -5.53
2017-09-30 -9.11
2017-06-30 -32.67
2017-03-31 -43.94
2016-12-31 -74.75
2016-09-30 -108.75
2016-06-30 -75.70

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cesca Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Cesca Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cesca Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

KOOL Past Performance

  How has Cesca Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cesca Therapeutics's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cesca Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Cesca Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cesca Therapeutics's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Cesca Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cesca Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:KOOL Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 10.77 -38.63 8.38 2.53
2018-12-31 9.67 -39.72 9.35 3.01
2018-09-30 9.93 -32.14 9.08 3.74
2018-06-30 9.88 -31.90 9.35 4.20
2018-03-31 11.38 -6.40 9.25 3.85
2017-12-31 12.77 -5.53 9.61 3.38
2017-09-30 13.83 -9.00 10.22 2.60
2017-06-30 14.53 -29.10 12.40 2.50
2017-03-31 14.00 -31.64 10.61 2.05
2016-12-31 13.58 -40.41 10.52 2.19
2016-09-30 12.87 -37.64 10.34 2.15
2016-06-30 11.93 -18.59 11.04 2.57
2016-03-31 12.65 -17.27 8.21 3.01
2015-12-31 13.86 -11.21 9.85 4.01
2015-09-30 15.21 -14.95 11.85 4.91
2015-06-30 16.04 -14.85 11.66 5.29
2015-03-31 16.18 -15.35 15.31 5.31
2014-12-31 16.17 -12.40 13.38 4.36
2014-09-30 16.00 -9.63 10.38 3.62
2014-06-30 15.99 -8.63 10.24 2.97
2014-03-31 16.30 -8.16 7.54 3.18
2013-12-31 17.15 -7.42 7.69 3.07
2013-09-30 17.49 -6.38 8.16 2.99
2013-06-30 17.96 -3.09 7.10 2.99
2013-03-31 18.30 -1.43 7.61 3.02
2012-12-31 18.31 -2.07 7.29 3.32
2012-09-30 18.29 -2.78 7.46 3.64
2012-06-30 19.02 -4.99 7.98 3.73

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cesca Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cesca Therapeutics has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cesca Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cesca Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cesca Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

KOOL Health

 How is Cesca Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cesca Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cesca Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cesca Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cesca Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 3.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cesca Therapeutics Company Filings, last reported 2 months ago.

NasdaqCM:KOOL Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 6.28 2.56 2.24
2018-12-31 6.73 1.17 2.40
2018-09-30 13.87 0.80 2.22
2018-06-30 8.96 7.20 3.07
2018-03-31 31.12 7.20 2.87
2017-12-31 33.21 6.70 3.51
2017-09-30 30.83 5.00 2.46
2017-06-30 30.84 3.50 3.62
2017-03-31 31.81 1.50 3.79
2016-12-31 33.66 0.00 4.90
2016-09-30 36.33 0.00 5.61
2016-06-30 32.27 2.49 5.84
2016-03-31 35.78 1.54 7.25
2015-12-31 32.19 0.06 2.94
2015-09-30 32.26 0.02 6.56
2015-06-30 34.90 0.00 3.36
2015-03-31 37.04 0.00 4.79
2014-12-31 41.56 0.00 8.36
2014-09-30 45.60 0.00 10.71
2014-06-30 48.70 0.00 14.81
2014-03-31 41.23 0.00 6.58
2013-12-31 9.63 0.00 2.33
2013-09-30 11.12 0.00 5.31
2013-06-30 13.32 0.00 6.88
2013-03-31 15.57 0.00 7.52
2012-12-31 16.55 0.00 7.52
2012-09-30 16.98 0.00 8.75
2012-06-30 15.90 0.00 7.88
  • Cesca Therapeutics's level of debt (40.8%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 40.8% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cesca Therapeutics has less than a year of cash runway based on current free cash flow.
  • Cesca Therapeutics has less than a year of cash runway if free cash flow continues to reduce at historical rates of -3.4% each year.
X
Financial health checks
We assess Cesca Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cesca Therapeutics has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

KOOL Dividends

 What is Cesca Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cesca Therapeutics dividends.
If you bought $2,000 of Cesca Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cesca Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cesca Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:KOOL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2012 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:KOOL Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cesca Therapeutics has not reported any payouts.
  • Unable to verify if Cesca Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cesca Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cesca Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cesca Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cesca Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cesca Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

KOOL Management

 What is the CEO of Cesca Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chris Xu
COMPENSATION $653,000
AGE 47
TENURE AS CEO 2.6 years
CEO Bio

Dr. Xiaochun Xu, also known as Chris, M.B.A. Ph.D., is the Founder, Chairman and Chief Executive Officer of Boyalife Group since July 2009. Dr. Xu has been the Chairman of Board and Chief Executive Officer of Cesca Therapeutics since November 13, 2017 and serves as its President. Dr. Xu served as Interim Chief Executive Officer of Cesca Therapeutics Inc. until November 2016. He has over 15 years of Managerial experience in biomedicine and the pharmaceutical industry and has been involved in the discovery and development of several blockbuster drugs. Since 2000 until 2008, he served as a Project Leader at Pfizer, as a Director of Research at two publicly-traded companies and from 2008-2009, as a Vice President at Founder Group, a major Chinese technology conglomerate with interests in information technology, pharmaceuticals, real estate, finance and commodities trading. He has been a Director of Cesca Therapeutics Inc. since March 2016. Dr. Xu’s expertise spans several diverse therapeutic arenas including arthritis and inflammation, cardiovascular disease, autoimmunity, oncology and diabetes. Dr. Xu is also a Member of the Board of Directors of majority owned subsidiary ThermoGenesis Corp. He has authored over 40 publications and won several international awards from various professional societies for excellence in biomedical research. Dr. Xu received his Ph.D. degree in Immunology from Washington University School of Medicine (St. Louis, USA) and an Executive MBA degree from Emory University (Atlanta, USA). Dr. Xu received his B.SC. in Biochemistry from the University of Saskatchewan.

CEO Compensation
  • Chris's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Chris's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Cesca Therapeutics management team in years:

2.1
Average Tenure
47
Average Age
  • The tenure for the Cesca Therapeutics management team is about average.
Management Team

Chris Xu

TITLE
Chairman of the Board
COMPENSATION
$653K
AGE
47
TENURE
2.6 yrs

Jeff Cauble

TITLE
Principal Financial & Accounting Officer
COMPENSATION
$209K
AGE
45
TENURE
2.3 yrs

Jim Xu

TITLE
Director
COMPENSATION
$123K
AGE
47
TENURE
1 yrs

Phil Coelho

TITLE
Chief Technology Officer
COMPENSATION
$2M
AGE
74
TENURE
1.9 yrs

Haihong Zhu

TITLE
President of ThermoGenesis
Board of Directors Tenure

Average tenure and age of the Cesca Therapeutics board of directors in years:

2.6
Average Tenure
48
Average Age
  • The average tenure for the Cesca Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Chris Xu

TITLE
Chairman of the Board
COMPENSATION
$653K
AGE
47
TENURE
2.6 yrs

Jim Xu

TITLE
Director
COMPENSATION
$123K
AGE
47
TENURE
2.6 yrs

Jeff Thomis

TITLE
Director
COMPENSATION
$42K
AGE
72
TENURE
2.4 yrs

Russell Medford

TITLE
Director
COMPENSATION
$47K
AGE
63
TENURE
2.3 yrs

Mark Westgate

TITLE
Director
COMPENSATION
$39K
AGE
48
TENURE
2.1 yrs

Solomon Hamburg

TITLE
Member of Clinical & Scientific Advisory Board
TENURE
5.1 yrs

Lars Norgren

TITLE
Member of Clinical Advisory Board
TENURE
3.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
30. Aug 18 Buy Joseph Thomis Individual 28. Aug 18 28. Aug 18 3,500 $1.80 $6,300
X
Management checks
We assess Cesca Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cesca Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

KOOL News

Simply Wall St News

Does The Cesca Therapeutics Inc. (NASDAQ:KOOL) Share Price Tend To Follow The Market?

This means that -- if history is a guide -- buying the stock would reduce the impact of overall market volatility in many portfolios (depending on the beta of the portfolio, of course). … Even when they are traded more actively, the share price is often more susceptible to company specific developments than overall market volatility. … What this means for you: Since Cesca Therapeutics is not heavily influenced by market moves, its share price is probably far more dependend on company specific developments.

Simply Wall St -

Did Changing Sentiment Drive Cesca Therapeutics's (NASDAQ:KOOL) Share Price Down A Disastrous 99%?

Check out our latest analysis for Cesca Therapeutics Cesca Therapeutics isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … Over half a decade Cesca Therapeutics reduced its trailing twelve month revenue by 10% for each year. … A Different Perspective Cesca Therapeutics shareholders are down 49% for the year, but the market itself is up 5.2%.

Simply Wall St -

Is Cesca Therapeutics Inc's (NASDAQ:KOOL) Balance Sheet Strong Enough To Weather A Storm?

How does KOOL’s operating cash flow stack up against its debt? … With this increase in debt, the current cash and short-term investment levels stands at US$3.62M , ready to deploy into the business. … Investors' risk associated with debt is very low with KOOL, and the company has plenty of headroom and ability to raise debt should it need to in the future.Next Steps: KOOL’s cash flow coverage indicates it could improve its operating efficiency in order to meet demand for debt repayments should unforeseen events arise.

Simply Wall St -

What You Must Know About Cesca Therapeutics Inc's (NASDAQ:KOOL) Major Investors

In this article, I'm going to take a look at Cesca Therapeutics Inc’s (NASDAQ:KOOL) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … With an institutional ownership of 3.51%, KOOL doesn't seem too exposed to higher volatility resulting from institutional trading. … However, ownership structure should not be the only determining factor when you’re building an investment thesis for KOOL.

Simply Wall St -

Is Cesca Therapeutics Inc (NASDAQ:KOOL) Growing Too Fast?

Additional cash raising may dilute the value of your shares, and since Cesca Therapeutics is currently burning more cash than it is making, it’s likely the business will need funding for future growth. … NasdaqCM:KOOL Income Statement Mar 12th 18 When will Cesca Therapeutics need to raise more cash? … However, if Cesca Therapeutics continues to grow its opex at this rate, given how much money it currently has in the bank, it will actually need to raise capital again in within the next 2 months!

Simply Wall St -

Are Earnings Prospects Improving For Loss-Making Cesca Therapeutics Inc's (NASDAQ:KOOL)?

Examining Cesca Therapeutics Inc's (NASDAQ:KOOL) past track record of performance is an insightful exercise for investors. … Check out our latest analysis for Cesca Therapeutics Commentary On KOOL's Past Performance For the purpose of this commentary, I like to use the ‘latest twelve-month’ data, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … Each year, for the past five years Cesca Therapeutics has seen an annual decline in revenue of -8.91%, on average.

Simply Wall St -

Is Cesca Therapeutics Inc (NASDAQ:KOOL) A Healthcare Leader?

Cesca Therapeutics Inc (NASDAQ:KOOL), a $32.29M small-cap, is a healthcare company operating in an industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasing prevalence of diseases and comorbidities. … In this article, I’ll take you through the sector growth expectations, and also determine whether Cesca Therapeutics is a laggard or leader relative to its healthcare sector peers. … Check out our latest analysis for Cesca Therapeutics What’s the catalyst for Cesca Therapeutics's sector growth?

Simply Wall St -

Is Cesca Therapeutics Inc (NASDAQ:KOOL) A Financially Sound Company?

KOOL's debt levels surged from $2.5M to $3.5M over the last 12 months , which is made up of current and long term debt. … With this rise in debt, KOOL currently has $3.6M remaining in cash and short-term investments , ready to deploy into the business. … However, its small level of operating cash flow means calculating cash-to-debt wouldn't be too useful, though these low levels of cash means that operational efficiency is worth a look.

Simply Wall St -

Does Cesca Therapeutics Inc's (KOOL) 91.6% Earnings Growth Make It An Outperformer?

Examining how Cesca Therapeutics Inc (NASDAQ:KOOL) is performing as a company requires looking at more than just a years' earnings. … For Cesca Therapeutics, the most recent twelve-month earnings -$9M, which, in comparison to the previous year's level, has become less negative. … Though Cesca Therapeutics's past data is helpful, it is only one aspect of my investment thesis.

Simply Wall St -

Who Owns Cesca Therapeutics Inc (KOOL)?

See our latest analysis for KOOL NasdaqCM:KOOL Ownership Summary Nov 3rd 17 Institutional Ownership Institutional investors are one of the largest group of market participants and their buy-sell decisions on a company's stock can significantly impact prices, more so, when there are relatively small amounts of shares available on the market to trade. … This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … Institutional ownership in KOOL is not at a level that would concern investors.

Simply Wall St -

KOOL Company Info

Description

Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies for cell-based therapies in the United States, China, rest of Asia, Europe, and internationally. The company operates through two segments, Clinical Development and Device. It offers AutoXpress System, an automated system for the isolation, collection and storage of hematopoietic stem cell concentrates derived from cord blood and peripheral blood; Point-of CareXpress System for the rapid, automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells; CAR-TXpress System that addresses the critical unmet need for chemistry, manufacturing and controls improvement of the emerging CAR-T therapies for cancer patients; BioArchive Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for stem cell samples and clinical products; and manual disposables. The company is also developing autologous stem cell-based therapeutics that address medical needs for applications in the vascular, cardiology, and orthopedic markets. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California.

Details
Name: Cesca Therapeutics Inc.
KOOL
Exchange: NasdaqCM
Founded: 1986
$6,574,697
2,364,914
Website: http://www.cescatherapeutics.com
Address: Cesca Therapeutics Inc.
2711 Citrus Road,
Rancho Cordova,
California, 95742,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM KOOL Common Stock Nasdaq Capital Market US USD 05. Jun 1987
DB THRN Common Stock Deutsche Boerse AG DE EUR 05. Jun 1987
MUN THRP Common Stock Boerse Muenchen DE EUR 05. Jun 1987
Number of employees
Current staff
Staff numbers
53
Cesca Therapeutics employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/24 23:45
End of day share price update: 2019/06/24 00:00
Last estimates confirmation: 2019/03/26
Last earnings filing: 2019/05/14
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.